JP2011528666A - 放出調節製剤及びその使用方法 - Google Patents

放出調節製剤及びその使用方法 Download PDF

Info

Publication number
JP2011528666A
JP2011528666A JP2011518947A JP2011518947A JP2011528666A JP 2011528666 A JP2011528666 A JP 2011528666A JP 2011518947 A JP2011518947 A JP 2011518947A JP 2011518947 A JP2011518947 A JP 2011518947A JP 2011528666 A JP2011528666 A JP 2011528666A
Authority
JP
Japan
Prior art keywords
formulation
retigabine
hours
release
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011518947A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528666A5 (enExample
Inventor
ナドジェソムバトイ ビルジャナ
Original Assignee
バレアント プハルマセウトイカルス インターナショナル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41550741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2011528666(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by バレアント プハルマセウトイカルス インターナショナル filed Critical バレアント プハルマセウトイカルス インターナショナル
Publication of JP2011528666A publication Critical patent/JP2011528666A/ja
Publication of JP2011528666A5 publication Critical patent/JP2011528666A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2011518947A 2008-07-18 2009-07-17 放出調節製剤及びその使用方法 Pending JP2011528666A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8216208P 2008-07-18 2008-07-18
US61/082,162 2008-07-18
PCT/US2009/051052 WO2010009433A1 (en) 2008-07-18 2009-07-17 Modified release formulation and methods of use

Publications (2)

Publication Number Publication Date
JP2011528666A true JP2011528666A (ja) 2011-11-24
JP2011528666A5 JP2011528666A5 (enExample) 2012-08-30

Family

ID=41550741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011518947A Pending JP2011528666A (ja) 2008-07-18 2009-07-17 放出調節製剤及びその使用方法

Country Status (16)

Country Link
US (1) US20100120906A1 (enExample)
EP (1) EP2318001A4 (enExample)
JP (1) JP2011528666A (enExample)
KR (1) KR20110052641A (enExample)
CN (1) CN102170879B (enExample)
AU (1) AU2009270768A1 (enExample)
BR (1) BRPI0916000A2 (enExample)
CA (1) CA2731008A1 (enExample)
CL (1) CL2011000109A1 (enExample)
CO (1) CO6351716A2 (enExample)
EA (1) EA201170230A1 (enExample)
IL (1) IL210683A0 (enExample)
MX (1) MX2011000636A (enExample)
NZ (1) NZ590885A (enExample)
WO (1) WO2010009433A1 (enExample)
ZA (1) ZA201102518B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009013613A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
DE102009013612A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
BR112012010201A2 (pt) 2009-11-03 2017-08-08 Lupin Ltd formulação de libertação modificada da lacosamida
SG181827A1 (en) 2010-01-20 2012-07-30 Glaxo Group Ltd Novel retigabine composition
BR112012018173A2 (pt) * 2010-01-20 2017-08-29 Valeant Pharmaceuticals Int "formulação de liberação modificada e método de uso"
JP2014510714A (ja) 2011-01-18 2014-05-01 グラクソ グループ リミテッド レチガビンの製造方法
CA3207643A1 (en) 2015-09-23 2017-03-30 XWPharma Ltd. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物
WO2021113381A1 (en) * 2019-12-02 2021-06-10 Xenon Pharmaceuticals Inc. Pediatric immediate-release formulation of the potassium channel opener ezogabine

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000086509A (ja) * 1998-09-14 2000-03-28 Taisho Yakuhin Kogyo Kk ソファルコン含有製剤の製造方法
WO2002043704A1 (fr) * 2000-12-01 2002-06-06 Kyowa Hakko Kogyo Co., Ltd. Composition a solubilite ou absorbabilite orale amelioree
JP2003528829A (ja) * 2000-03-08 2003-09-30 アーヴェーデー．ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 薬剤学的製剤
JP2004131393A (ja) * 2002-10-08 2004-04-30 Kowa Co 易溶出性製剤
JP2004518653A (ja) * 2000-12-20 2004-06-24 ワイス 不安障害を治療する方法
JP2004528358A (ja) * 2001-05-09 2004-09-16 ノバルティス アクチエンゲゼルシャフト シクロスポリン含有医薬組成物
JP2004536108A (ja) * 2001-07-03 2004-12-02 ファーム テック リサーチ，インコーポレーテッド アセクロフェナックを含有する経済的な経口用製剤の組成及び製法
JP2005508946A (ja) * 2001-10-09 2005-04-07 アストラゼネカ アクチボラグ 医薬製剤
JP2006506353A (ja) * 2002-09-17 2006-02-23 ワイス 経口処方
JP2007500163A (ja) * 2003-07-30 2007-01-11 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ２，５−ジヒドロキシベンゼンスルホン酸化合物およびカリウムイオンチャンネル調節剤を含む活性物質組合せ
WO2007034503A2 (en) * 2005-06-20 2007-03-29 Cadila Healthcare Limited Controlled release dosage formulation of duloxetine

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) * 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
JP2003506388A (ja) * 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド 疼痛および不安症を処置または予防するための方法
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes
AR033095A1 (es) * 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
GB0120835D0 (en) * 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1524981B1 (en) * 2002-07-29 2009-03-11 Glaxo Group Limited Sustained release formulations comprising lamotrigine
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
US20070259033A1 (en) * 2003-09-26 2007-11-08 Evangeline Cruz Controlled release formulations exhibiting an ascending rate of release
GB0324574D0 (en) * 2003-10-21 2003-11-26 Glaxo Group Ltd Novel compositions
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
WO2006044202A2 (en) * 2004-10-19 2006-04-27 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
JP5543110B2 (ja) * 2006-01-05 2014-07-09 エッセンシャリス，インク． カリウムａｔｐチャネルオープナの塩およびその使用
US8558470B2 (en) * 2006-01-20 2013-10-15 Point Somee Limited Liability Company Adaptive current regulation for solid state lighting
USD601689S1 (en) * 2006-05-12 2009-10-06 Glaxo Group Limited Pharmaceutical tablet
BRPI0719590A2 (pt) * 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000086509A (ja) * 1998-09-14 2000-03-28 Taisho Yakuhin Kogyo Kk ソファルコン含有製剤の製造方法
JP2003528829A (ja) * 2000-03-08 2003-09-30 アーヴェーデー．ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 薬剤学的製剤
WO2002043704A1 (fr) * 2000-12-01 2002-06-06 Kyowa Hakko Kogyo Co., Ltd. Composition a solubilite ou absorbabilite orale amelioree
JP2004518653A (ja) * 2000-12-20 2004-06-24 ワイス 不安障害を治療する方法
JP2004528358A (ja) * 2001-05-09 2004-09-16 ノバルティス アクチエンゲゼルシャフト シクロスポリン含有医薬組成物
JP2004536108A (ja) * 2001-07-03 2004-12-02 ファーム テック リサーチ，インコーポレーテッド アセクロフェナックを含有する経済的な経口用製剤の組成及び製法
JP2005508946A (ja) * 2001-10-09 2005-04-07 アストラゼネカ アクチボラグ 医薬製剤
JP2006506353A (ja) * 2002-09-17 2006-02-23 ワイス 経口処方
JP2004131393A (ja) * 2002-10-08 2004-04-30 Kowa Co 易溶出性製剤
JP2007500163A (ja) * 2003-07-30 2007-01-11 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ２，５−ジヒドロキシベンゼンスルホン酸化合物およびカリウムイオンチャンネル調節剤を含む活性物質組合せ
WO2007034503A2 (en) * 2005-06-20 2007-03-29 Cadila Healthcare Limited Controlled release dosage formulation of duloxetine

Also Published As

Publication number Publication date
WO2010009433A1 (en) 2010-01-21
CN102170879B (zh) 2014-03-05
CN102170879A (zh) 2011-08-31
CO6351716A2 (es) 2011-12-20
AU2009270768A1 (en) 2010-01-21
IL210683A0 (en) 2011-03-31
CA2731008A1 (en) 2010-01-21
ZA201102518B (en) 2012-06-27
EP2318001A4 (en) 2013-02-20
US20100120906A1 (en) 2010-05-13
EP2318001A1 (en) 2011-05-11
MX2011000636A (es) 2011-08-03
BRPI0916000A2 (pt) 2019-09-24
NZ590885A (en) 2013-01-25
EA201170230A1 (ru) 2011-08-30
CL2011000109A1 (es) 2011-11-25
KR20110052641A (ko) 2011-05-18

Similar Documents

Publication Publication Date Title
US20230081113A1 (en) Modified release preparations containing oxcarbazepine and derivatives thereof
CN102946869B (zh) γ-羟基丁酸的速释制剂及剂型
JP2011528666A (ja) 放出調節製剤及びその使用方法
US20100323016A1 (en) Modified release formulation and methods of use
US8709485B2 (en) Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
JPH07558B2 (ja) モピダモール製剤
TW201206501A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
RU2738114C2 (ru) Пероральные фармацевтические композиции никотинамида
US20100323015A1 (en) Modified release formulation and methods of use
JP2025512011A (ja) デフェリプロンを含む修飾放出医薬製剤
JP2009525953A (ja) ジバルプロ酸及びその誘導体の徐放性製剤
US9180110B2 (en) Pharmaceutical compositions of fenofibrate
AU2013200237B2 (en) Controlled released preparations of oxcarbazepine having sigmoidal release profile
EP2525660A1 (en) Modified release formulation and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140701